Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer

Journal of Clinical Oncology

Volumn 17, Issue 7, 1999, Pages 2061-2068

  Baekelandt, M ^a   Kristensen, G B ^a   Nesland, J M ^a   Trope C G ^a   Holm, R ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIRUBICIN; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LAPAROTOMY; MAJOR CLINICAL STUDY; OVARY CANCER; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR BIOPSY;

EID: 0033024368     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.7.2061     Document Type: Article

References (50)

1. Kristensen G, Tropé C: Epithelial ovarian carcinoma. Lancet 349:113-117, 1997
2. Kerr J, Wyllie A, Currie A: Apoptosis: A basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 26:239-257, 1972
3. Lehnert M: Clinical multidrug resistance in cancer: A multifactorial problem. Eur J Cancer 32A:912-920, 1996
4. White E: Life, death, and the pursuit of apoptosis. Genes Dev 10:1-15, 1996
5. Bartek J, Bartkova J, Vojtesek B, et al: Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6:1699-1703, 1991
6. Hawkins D, Demers G, Galloway D: Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56:892-898, 1996
7. Flørenes V, Mælandsmo G, Forus A, et al: MDM2 gene amplification and gene transcript levels in human sarcomas: Relationship to TP53 gene status. J Natl Cancer Inst 86:1297-1302, 1994
8. Reifenberger G, Liu L, Ichimura K, et al: Amplification and overexpression of the mdm2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53:2736-2739, 1993
9. Miyashita T, Reed J: Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI 7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 52:5407-5411, 1992
10. Serov S, Scully R, Sobin L: Histological typing of ovarian tumors, in World Health Organization: International Histological Classification of Tumors (vol 9). Geneva, Switzerland, World Health Organization, 1973, pp 37-42
11. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
12. Cox DR: Regression models and life tables (with discussion). J R Stat Soc 34:187-209, 1972
13. Diebold J, Baretton G, Felchner M, et al: Bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol 105:341-349, 1996
14. Eltabbakh G, Belinson J, Kennedy A, et al: p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer 80:892-898, 1997
15. Levesque M, Katsaros D, Yu H, et al: Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 75:1327-1338, 1995
16. Skilling J, Sood A, Niemann T, et al: An abundance of p53 null mutations in ovarian carcinoma. Oncogene 13:117-123, 1996
17. Kihana T, Tsuda H, Teshima S, et al: High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy. Jpn J Cancer Res 83:978-984, 1992
18. Hartmann L, Podratz K, Keeney G, et al: Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 12:64-69, 1994
19. Klemi P, Pylkkänen L, Kiilholma P, et al: p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian cancer. Cancer 76:1201-1208, 1995
20. Foulkes W, Stamp G, Afzal S, et al: MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. Br J Cancer 72:883-888, 1995
21. Courjal F, Cuny M, Rodriguez C, et al: DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumors. Br J Cancer 74:1984-1989, 1996
22. Tanner B, Hengstler J, Laubscher S, et al: mdm2 mRNA is associated with survival in ovarian cancer. Int J Cancer (Pred Oncol) 74:438-442, 1997
23. Skomedal H, Kristensen G, Abeler V, et al: TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas. J Pathol 181:158-165, 1997
24. Landers J, Haines D, Strauss J, et al: Enhanced translation: A novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 9:2745-2750, 1994
25. Momand J, Zambetti G, Olson D, et al: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245, 1992
26. Haupt Y, Maya R, Kazaz A, et al: Mdm2 promotes the rapid degradation of p53. Nature 387:296-299, 1997
27. s in normal and neoplastic ovarian tissues. Clin Cancer Res 4:517-524, 1998
28. Herod J, Eliopoulos A, Warwick J, et al: The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56:2178-2184, 1996
29. Marx D, Binder C, Meden H, et al: Differential expression of apoptosis associated genes bax and Bcl-2 in ovarian cancer. Anticancer Res 17:2233-2240, 1997
30. Henriksen R, Wilander E, Oberg K: Expression and prognostic significance of Bcl-2 in ovarian tumours. Br J Cancer 72:1324-1329, 1995
31. Eliopoulos A, Kerr D, Herod J, et al: The control of apoptosis and drug resistance in ovarian cancer: Influence of p53 and Bcl-2. Oncogene 11:1217-1228, 1995
32. Righetti S, Della Torre G, Pilotti S, et al: A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 56:689-693, 1996
33. Smith-Sørensen B, Kærn J, Holm R, et al: Therapy effect of either paclitaxel or cyclophosphamide treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. Br J Cancer 78:375-381, 1998
34. van der Zee A, Hollema H, Suurmeijer A, et al: Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 13:70-78, 1995
35. De Feudis P, Debernardis D, Beccaglia P, et al: DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status. Br J Cancer 76:474-479, 1997
36. Hickman J: Apoptosis and chemotherapy resistance. Eur J Cancer 32A:921-926, 1996
37. Reed J: Bcl-2 family proteins: Regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 34:9-19, 1997 (suppl 5)
38. Fan S, El Deiry W, Bae I, et al: p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA-damaging agents. Cancer Res 54:5824-5830, 1994
39. Livingstone L, White A, Sprouse J, et al: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-935, 1992
40. Wahl A, Donaldson K, Fairchild C, et al: Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 2:72-79, 1996
41. Dittmer D, Pati S, Zambetti G, et al: Gain of function mutations in p53. Nat Genet 4:42-45, 1993
42. Chin K, Ueda K, Pastan I, et al: Modulation of activity of the promotor of the human MDR J gene by Ras and p53. Science 255:459-462, 1992
43. Kieser A, Weich H, Brandner G, et al: Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9:963-969, 1994
44. Asschert J, Vellenga E, Hollema H, et al: Expression of macrophage colony-stimulating factor (M-CSF), interleukin-6 (IL-6), interleukin-11 (IL-11) and tumor necrosis factor-alpha (TNF-α) in p53-characterized human ovarian carcinomas. Eur J Cancer 33:2246-2251, 1997
45. Pietenpol J, Papadopoulos N, Markowitz S, et al: Paradoxical inhibition of solid tumor cell growth by Bcl-2. Cancer Res 54:3714-3717, 1994
46. Brady HJ, Gil-Gomez G, Kirberg J, et al: Bax-alpha perturbs T cell development and affects cell cycle entry of T cells. EMBO J 15:6991-7001, 1996
47. McDonell TJ, Deane N, Platt FM, et al: Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57:79-88, 1989
48. Koukourakis M, Giatromanolaki A, O'Byrne K, et al: Potential role of Bcl-2 as a suppressor of tumor angiogenesis in non-small cell lung cancer. Int J Cancer (Pred Oncol) 74:565-570, 1997
49. Gasparini G, Barbareschi M, Doglioni C, et al: Expression of Bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1:189-198, 1995
50. Pezzella F, Turley H, Kuzu I, et al: Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329:690-694, 1993